Safety and Efficacy of ABX-101 in Participants Aged 18 to 50 Years of Age With Moderate to Severe Traumatic Brain Injury
Study Details
Study Description
Brief Summary
The purpose of this study is to investigate the clinical improvement measured by the Glasgow Outcome Scale Extended (GOS-E) with ABX-101 compared with Placebo intramuscular injection in participants with moderate to severe TBI.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
Study details include:
-
The study duration will be up to 180 days per participant.
-
The treatment duration will be up to 7 days.
-
The visits post-treatment will be on day 30 and day 180 of the study.
Number of Participants:
A maximum of 45 participants will be enrolled into the study and randomized to each treatment arm in a ratio of 1:1:1. i.e., fifteen participants per arm.
Study Arms and Duration:
Participants will be screened, enrolled and receive the assigned treatment within 12 hours of the primary TBI insult. Enrolled participants will be stratified 1:1 (in each arm) by GCS score (GCS 4-8 in one group and GCS 9 - 12 in the other). The treatment period, which involves 6 hourly, i.e., quarter in die (QID), ABX-101 (1 mg OR 2 mg) intramuscular injections, is seven days. Enrolled participant will continue with the in-hospital standard of care, as decided by the external treating physician, and will be followed up by the study team on days 30 and days 180. The ABX-101 1 mg and 2 mg arm will be enrolled simultaneously.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Experimental: ABX-101 1mg Participants will be screened, enrolled and receive the assigned treatment within 12 hours of the primary TBI insult (or estimated less than 12 hours if the exact time is unknown). Enrolled participants will be stratified 1:1 (in each arm) by GCS score (GCS 4-8 in one group and GCS 9 - 12 in the other). The treatment period, which involves 6 hourly, i.e., quarter in die (QID), ABX 101 (1 mg OR 2 mg) intramuscular injections, is seven days. |
Drug: ABX-101 1mg
ABX-101 1mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)
Drug: ABX-101 2mg
ABX-101 2mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)
|
| Experimental: Experimental: ABX-101 2mg Participants will be screened, enrolled and receive the assigned treatment within 12 hours of the primary TBI insult (or estimated less than 12 hours if the exact time is unknown). Enrolled participants will be stratified 1:1 (in each arm) by GCS score (GCS 4-8 in one group and GCS 9 - 12 in the other). The treatment period, which involves 6 hourly, i.e., quarter in die (QID), ABX 101 (1 mg OR 2 mg) intramuscular injections, is seven days. |
Drug: ABX-101 1mg
ABX-101 1mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)
Drug: ABX-101 2mg
ABX-101 2mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)
|
| Placebo Comparator: Placebo Comparator: Saline Placebo to the ABX-101 will be administered to patients. |
Drug: ABX-101 1mg
ABX-101 1mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)
Drug: ABX-101 2mg
ABX-101 2mg will be provided to patients stratified 1:1 by GCS scoring (GCS 4-8; GCS 9-12)
|
Outcome Measures
Primary Outcome Measures
- Glasgow Outcome Scale-Extended (GOS-E) [180 days]
To demonstrate superiority of ABX-101 vs placebo on the Glasgow Outcome Scale-Extended (GOS-E) at 90-days in participants with TBI
Secondary Outcome Measures
- Glasgow Outcome Scale-Extended (GOS-E) [30 days]
To demonstrate superiority of ABX-101 vs placebo on the GOS-E at 30 days in participants with TBI
- Glasgow Coma Score (GSC) improvement [7 days]
To demonstrate superiority of ABX-101 vs placebo on the GCS improvement (vs. baseline) at days 3 and 7 in participants with TBI
- ICP Maintenance [7 days]
To demonstrate superiority of ABX-101 vs placebo on the ICP maintenance at 3 days and 7 days in participants with TBI
- Midline Shift [3 days]
To demonstrate superiority of ABX-101 vs placebo on the degree of midline shift as assessed by CT scan at 1 day and 3 days in participants with TBI
- Therapeutic Intensity Level [7 days]
To demonstrate superiority of ABX-101 vs placebo on the Therapeutic Intensity Level over 3 days and over 7 days in participants with TBI
- Neuroworsening [7 days]
To demonstrate superiority of ABX-101 vs placebo on the Neuroworsening at 3 days and 7 days in participants with TBI
- Mortality [180 days]
To demonstrate superiority of ABX-101 vs placebo on the mortality at 3 days, 7 days, 28 days, and 90 days in participants with TBI
- Quality of life- (QOLIBRI) [180 days]
To demonstrate superiority of ABX-101 vs placebo on the Quality of Life after Brain Injury at 90 days in participants with TBI
- GFAP Inflammatory Biomarker Analysis [7 days]
To compare ABX-101 vs placebo on Glial fibrillary acidic protein (GFAP) levels at 1 day, 3 days, and 7 days in participants with TBI. The detection range for GFAP biomarker is 0.31 - 20 ng/ml using ELAB Science GFAP Kit.
- Adverse Events [7 days]
To compare ABX-101 vs placebo in terms of AEs assessed over 7 days of treatment and through the duration of follow-up in participants with TBI
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Written informed consent from patient, patient's legal guardian or legal representative, or deferred consent procedure, according to local requirements
-
18 - 50 years of age, inclusive
-
Expected to survive more than 24 hours after admission
-
Clearly defined time of injury no more than 12 hours before administration of study drug/placebo
o Subjects stratified 1:1 (in each arm) by treatment administered 0-12 hrs
- TBI with Glasgow Coma Score (GCS) 4-12 requiring intracranial pressure (ICP) monitoring according to the assessment of the treating physician
o Subjects stratified 1:1 (in each arm) by GCS 4-8 and GCS 9-12
-
Catheter placement (intraventricular or intraparenchymal, only) for monitoring and management of increased ICP
-
[Brain computed tomography (CT) showing intracranial parenchymal abnormality and hemodynamically stable]
Exclusion Criteria:
-
Penetrating head injury (e.g. missile, stab wound)
-
Concurrent, but not pre-existing, spinal cord injury
-
Not expected to survive more than 24 hours after admission
-
Pregnant, or a positive pregnancy test
-
Coma due to an exclusive epidural hematoma (lucid interval and absence of structural brain damage on CT scan)
-
Patient pupils are unresponsive (dilation) in both eyes
-
The subject has a neurodegenerative disease or other neurological disorder including dementia, Parkinson's disease, multiple sclerosis, seizure disorder, or brain tumors.
-
Coma suspected to be primarily due to other causes than head injury (e.g. drug overdose intoxication, drowning/near drowning
-
Known or CT scan evidence of pre-existing major cerebral damage
-
Any severe concomitant condition (cancer; hematologic, renal, hepatic, coronary disease; major psychiatric disorder; alcohol or drug abuse), that can be ascertained at admission
-
Known to have received an experimental drug within 4 weeks prior to current injury
-
Patients who cannot be monitored with regard to their recovery (GOS-E and QOLIBRI)
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Abalonex, LLC
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ABX-TBI-001